Hansa Biopharma
28.94 SEK
-1.09 %
Less than 1K followers
HNSA
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Valuation
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Hansa Biopharma
EV/S
Median 2019-2025
P/B
Median 2019-2025
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Share price (SEK) | 83.85 | 240.40 | 88.80 | 49.22 | 26.20 | 39.20 | 34.36 |
| Shares | 40.0 | 41.4 | 46.3 | 52.4 | 52.7 | 67.8 | 101.8 |
| Market cap | 3,356.2 | 9,953.8 | 4,114.5 | 2,581.3 | 1,380.0 | 2,658.3 | 3,496.6 |
| Enterprise value | 2,765.3 | 8,581.3 | 3,261.0 | 1,876.2 | 1,514.7 | 3,332.0 | 3,729.3 |
| EV/S | 822.0 | 1,407.2 | 96.3 | 12.1 | 11.3 | 19.4 | 16.8 |
| EV/EBITDA | neg. | neg. | neg. | neg. | neg. | neg. | neg. |
| EV/EBIT | neg. | neg. | neg. | neg. | neg. | neg. | neg. |
| P/E | neg. | neg. | neg. | neg. | neg. | neg. | neg. |
| P/B | 5.96 | 8.02 | 5.43 | 4.26 | -8.22 | -4.51 | -41.56 |
| P/S | 997.7 | 1,632.3 | 121.5 | 16.7 | 10.3 | 15.5 | 15.7 |
| Dividend yield | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % |
| Equity ratio | 84.7 % | 86.6 % | 74.8 % | 35.9 % | -16.5 % | -73.6 % | -7.2 % |
| Gearing ratio | 1.8 % | 0.4 % | 4.7 % | 130.6 % | -516.3 % | -183.1 % | -1,110.0 % |